Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease.

[1]  C. Siegrist,et al.  High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease. , 2019, The American journal of gastroenterology.

[2]  B. Feagan,et al.  Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease , 2019, Alimentary pharmacology & therapeutics.

[3]  F. Eser,et al.  High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study , 2019, Human vaccines & immunotherapeutics.

[4]  S. Grisaru-Granovsky,et al.  Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study. , 2019, The American journal of gastroenterology.

[5]  L. Lynd,et al.  Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study , 2019, BMJ Open.

[6]  O. Mir,et al.  Treating Ulcerative Colitis During Pregnancy: Evidence of Materno-Fetal Transfer of Golimumab. , 2018, Journal of Crohn's & colitis.

[7]  W. Czuber-Dochan,et al.  Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients′ reproductive health , 2018, Alimentary pharmacology & therapeutics.

[8]  M. Neurath,et al.  Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease. , 2018, Journal of Crohn's & colitis.

[9]  D. Franchimont,et al.  Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab , 2018, Journal of Crohn's & colitis.

[10]  F. Huang,et al.  Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials , 2018, Clinical Rheumatology.

[11]  M. Lukáš,et al.  Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation. , 2018, Inflammatory bowel diseases.

[12]  C. J. van der Woude,et al.  Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero , 2018, Journal of Crohn's & colitis.

[13]  J. Kjeldsen,et al.  Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[14]  X. Roblin,et al.  Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy , 2018, Annals of Internal Medicine.

[15]  S. Feldman,et al.  Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis , 2018, Inflammatory bowel diseases.

[16]  A. Barkun,et al.  Continuous Anti‐TNF&agr; Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION) , 2018, The American Journal of Gastroenterology.

[17]  H. Valdez,et al.  T‐cell–mediated immune response to pneumococcal conjugate vaccine (PCV‐13) and tetanus toxoid vaccine in patients with moderate‐to‐severe psoriasis during tofacitinib treatment , 2018, Journal of the American Academy of Dermatology.

[18]  T. Burt,et al.  Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants , 2018, Clinical and Translational Gastroenterology.

[19]  S. Saha,et al.  Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients , 2018, Digestive Diseases and Sciences.

[20]  D. Murphy,et al.  Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. , 2018, Journal of Crohn's & colitis.

[21]  J. Gisbert,et al.  Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study , 2018, The American Journal of Gastroenterology.

[22]  A. Moss,et al.  Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis , 2017, World journal of gastroenterology.

[23]  F. Carrat,et al.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease , 2017, JAMA.

[24]  X. Mariette,et al.  Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study , 2017, Annals of the rheumatic diseases.

[25]  M. Juan,et al.  Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy , 2017, Front. Immunol..

[26]  W. Sandborn,et al.  Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. , 2017, Gastroenterology clinics of North America.

[27]  B. Flourié,et al.  Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature , 2017, BMC Gastroenterology.

[28]  T. Wyant,et al.  A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab , 2017, Clinical Pharmacokinetics.

[29]  U. Demkow,et al.  Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study , 2017, Inflammatory bowel diseases.

[30]  M. Dubinsky,et al.  Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[31]  Noor B. Dawany,et al.  Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[32]  D. Rubin,et al.  Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis , 2016, Digestive Diseases and Sciences.

[33]  Terry S Baker,et al.  Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. , 2016, Journal of reproductive immunology.

[34]  U. Kopylov,et al.  Perception of Reproductive Health in Women with Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[35]  Steven J Brown,et al.  Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. , 2016, Gastroenterology.

[36]  S. Feldman,et al.  Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis , 2016, Drug Safety.

[37]  A. Madill,et al.  What Factors Might Drive Voluntary Childlessness (VC) in Women with IBD? Does IBD-specific Pregnancy-related Knowledge Matter? , 2016, Journal of Crohn's & colitis.

[38]  Christopher F. Martin,et al.  437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry , 2016 .

[39]  A. Bitton,et al.  The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.

[40]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[41]  H. Sørensen,et al.  Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[42]  M. Dubinsky,et al.  The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response , 2016, Digestive Diseases and Sciences.

[43]  T. Torres,et al.  Safety of Anti‐TNF Therapies in Immune‐Mediated Inflammatory Diseases: Focus on Infections and Malignancy , 2015, Drug development research.

[44]  D. Kennedy,et al.  Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. , 2015, British journal of clinical pharmacology.

[45]  Nattapaun N. Thepyasuwan,et al.  Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[46]  J. Walkowiak,et al.  Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[47]  C. J. van der Woude,et al.  Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety , 2015, Gut.

[48]  S. Travis,et al.  Introducing vedolizumab to clinical practice: who, when, and how? , 2015, Journal of Crohn's & colitis.

[49]  E. Lee,et al.  The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[50]  C. J. van der Woude,et al.  The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.

[51]  T. Leblanc,et al.  Anti–TNF-α Therapy May Cause Neonatal Neutropenia , 2014, Pediatrics.

[52]  B. Sands,et al.  Anti-TNF&agr; Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2014, Inflammatory bowel diseases.

[53]  F. Granath,et al.  Birth Outcomes in Women with Inflammatory Bowel Disease: Effects of Disease Activity and Drug Exposure , 2014, Inflammatory bowel diseases.

[54]  M. Østensen.  Safety issues of biologics in pregnant patients with rheumatic diseases , 2014 .

[55]  Eun Soo Kim,et al.  Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. , 2014, Journal of Crohn's & colitis.

[56]  B. Sands,et al.  Mo1194 Anti-TNFα Therapies Are Safe During Pregnancy in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2014 .

[57]  B. Feagan,et al.  Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results , 2014, Gut.

[58]  M. Lukáš,et al.  Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children , 2014, Inflammatory bowel diseases.

[59]  K. Papp,et al.  Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. , 2013, Journal of drugs in dermatology : JDD.

[60]  M. Lukáš,et al.  Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study , 2013, Scandinavian journal of gastroenterology.

[61]  G. Lichtenstein,et al.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. , 2013, World journal of gastroenterology.

[62]  M. Dubinsky,et al.  Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  E. Kuipers,et al.  Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[64]  P. Deepak,et al.  T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study , 2013, The American Journal of Gastroenterology.

[65]  P. Rutgeerts,et al.  Review article: non‐malignant haematological complications of anti‐tumour necrosis factor alpha therapy , 2012, Alimentary pharmacology & therapeutics.

[66]  C. Steenholdt,et al.  Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. , 2012, Journal of Crohn's & colitis.

[67]  S. Hutfless,et al.  Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease , 2011, The American Journal of Gastroenterology.

[68]  L. Peyrin-Biroulet,et al.  Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study* , 2011, Inflammatory bowel diseases.

[69]  E. Kuipers,et al.  High intra‐uterine exposure to infliximab following maternal anti‐TNF treatment during pregnancy , 2011, Alimentary pharmacology & therapeutics.

[70]  S. Travis,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics , 2011, The American Journal of Gastroenterology.

[71]  M. Hines,et al.  Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. , 2010, Journal of medicinal chemistry.

[72]  S. Shariq,et al.  Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. , 2010, Journal of Crohn's & colitis.

[73]  Noritaka Imai,et al.  Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. , 2010, Birth defects research. Part B, Developmental and reproductive toxicology.

[74]  S. Targan,et al.  Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[75]  C. Heijnen,et al.  Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment , 2008, Journal of leukocyte biology.

[76]  M. Dubinsky,et al.  499 The Effect of Maternal Peripartum Infliximab Use On Neonatal Immune Response , 2008 .

[77]  S. Targan,et al.  Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[78]  E. Butcher,et al.  Functional involvement of P‐selectin and MAdCAM‐1 in the recruitment of α4β7‐integrin‐expressing monocyte‐like cells to the pregnant mouse uterus , 2004, European journal of immunology.

[79]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[80]  A. Gaultier,et al.  Integrins: Regulators of embryogenesis , 2000, Biology of the cell.

[81]  G. Kollias,et al.  Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response , 1996, The Journal of experimental medicine.

[82]  R. Hynes,et al.  Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. , 1995, Development.

[83]  Christopher F. Martin,et al.  Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[84]  C. Chambers,et al.  Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[85]  M. Ostensen,et al.  Safety issues of biologics in pregnant patients with rheumatic diseases , 2014, Annals of the New York Academy of Sciences.

[86]  N. Parameswaran,et al.  Tumor necrosis factor-α signaling in macrophages. , 2010, Critical reviews in eukaryotic gene expression.